In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

How Sustainable Is England’s Cancer Drugs Fund?

The Cancer Drugs Fund has improved access to oncology drugs, but if it is to remain fit for purpose it will need to evolve.

Europe United Kingdom

How To Make Cross-Country Collaborations On Pricing Work

Francis Arickx from the cross-country coalition BeNeLuxA spoke this month about how the initiative had delivered proof of concept and discussed why uniting across borders is important for delivering access to transformative but expensive medicines.  

Europe Health Technology Assessment

WTO Price Transparency Talks Face Resistance From Developed Countries

Last week the World Trade Organization’s TRIPS Council discussed transparency in medicine pricing, including R&D costs.

South Africa Intellectual Property

Vertex Finally Inks Orkambi Deal In England

Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.

Companies Reimbursement

At Last: Vertex Strikes CF Deal In England

After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.

Europe United Kingdom

Vertex Strikes Spanish Payment-For-Results CF Deal

Vertex has struck a reimbursement deal in Spain for Orkambi and hopes that it will also make progress in England where a new proposal has been made by the company.

Europe Spain
See All
UsernamePublicRestriction

Register